EC approves AstraZeneca’s Brilique at a new 60mg dose
The European Commission (EC) has granted marketing authorisation to AstraZeneca’s Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
Click on this link for more information.
